Novo Nordisk A/S (LON: 0QIU)

London flag London · Delayed Price · Currency is GBP · Price in DKK
740.40
-6.80 (-0.91%)
Dec 20, 2024, 8:25 AM BST
8.52%
Market Cap 289.50B
Revenue (ttm) 30.19B
Net Income (ttm) 10.57B
Shares Out n/a
EPS (ttm) 2.37
PE Ratio 27.39
Forward PE n/a
Dividend n/a
Ex-Dividend Date Aug 15, 2024
Volume 3,963
Open 730.10
Previous Close 747.20
Day's Range 730.10 - 754.20
52-Week Range 678.00 - 1,032.20
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 5, 2025

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Pharmaceutical Preparations
Founded 1923
Employees 64,319
Stock Exchange London Stock Exchange
Ticker Symbol 0QIU
Full Company Profile

Financial Performance

In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.